

**WYOMING MEDICAID
Preferred Drug List (PDL) - April 20, 2015**

Drug classes not included on this list are not managed through a Preferred Drug List (PDL).
HOWEVER, THIS EXCLUSION IS NOT A GUARANTEE OF PAYMENT OR COVERAGE. Dosage limits and other requirements may apply.
Drugs new to market are non-preferred until a clinical review has been completed. PA criteria will apply to both the pediatric population,
as well as the adult population for those plans where PA/PDL limits are allowed.
Unless otherwise noted on the PDL, generic substitution is mandatory.

Yellow highlighted items below indicate new changes to the PDL. Red font indicates quantity/dosage limits apply. *Indicates BRAND is Preferred. May Use DAW 5.
Contact the GHS PA Helpdesk @ 877-207-1126 for prior authorization if client has primary insurance that will not cover the brand name medication.

**Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid
Provider Manual at <http://wymedicaid.org> for additional criteria.**

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>PLEASE CONTACT GHS FOR QUESTIONS</small>
ADDICTION AGENTS	BUPRENORPHINE COMBINATIONS		Client must have a diagnosis of opioid dependence or abuse. This is not to be used for the treatment of chronic pain. Prescriber must have a XDEA number. Prior authorization will be required before any narcotic or carisoprodol prescription will be allowed between fills. Prior authorization will be required before any benzodiazepine or short-acting stimulant prescription from any doctor other than the prescriber of buprenorphine or Suboxone, will be allowed between fills. Oral buprenorphine will be approved for clients that are pregnant or nursing or with a documented allergy to naloxone. Dosage limits apply (Max Dose: 24mg/day). Client is limited to two (2) years of buprenorphine/naloxone or oral buprenorphine use. Please submit PA requests on the "Oral Buprenorphine/Naloxone or Oral Buprenorphine" PA form available at www.wymedicaid.org .	BUNAVAIL buprenorphine (oral) buprenorphine/naloxone tablets (use preferred) ZUBSOLV
		SUBOXONE FILM		
	NALTREXONE		Client must have a diagnosis of alcohol or opioid dependence. Prior authorization will be required before any narcotic or carisoprodol prescription will be allowed between fills. Prior authorization will be required before any benzodiazepine or short-acting stimulant prescription from any doctor other than the prescriber of buprenorphine or Suboxone, will be allowed between fills.	
		naltrexone VIVITROL		
ALLERGY / ASTHMA	ANTIHISTAMINES, MINIMALLY SEDATING		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	desloratadine CLARINEX RDT/SYRUP levocetirizine
	cetirizine fexofenadine loratadine			
	ANTIHISTAMINE/DECONGESTANT COMBINATIONS			
	cetirizine/pseudoephedrine fexofenadine/pseudoephedrine loratadine/pseudoephedrine		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	CLARINEX-D
	ANTICHOLINERGIC BRONCHODILATORS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Spiriva 5 day STARTER package will be allowed one (1) time per recipient.	ATROVENT HFA INCRUSE ELLIPTA TUDORZA
	COMBIVENT ipratropium SPIRIVA			
	CORTICOSTEROID / BRONCHODILATOR COMBO'S		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. ***Will also require the diagnosis of COPD. **Advair HFA will be approved for clients 6 years of age and younger Advair 7 and 14-day STARTER package will be allowed one (1) time per recipient.	ADVAIR HFA** ANORO ELLIPTA*** BREQ ELLIPTA***
	ADVAIR DISK DULERA SYMBICORT			
	LEUKOTRIENE MODIFIERS		Trial and failure of preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	zafirlukast ZYFLO
	montelukast			
	LONG ACTING BRONCHODILATORS		Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	PERFOROMIST STRIVERDI
	BROVANA FORADIL SEREVENT			
	NASAL ANTIHISTAMINES		Trial and failure of preferred agent greater than or equal to 90 days in the last 12 months will be required before approval can be given for a non-preferred agent.	azelastine 0.15% DYMISTA (use separate agents) olopatadine 0.6%
	ASTELIN azelastine 0.1%			
	NASAL STEROIDS		Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Budesonide will be approved for pregnancy.	budesonide DYMISTA (use separate agents) OMNARIS QNASL triamcinolone VERAMYST ZETONNA
BECONASE AQ flunisolide fluticasone NASONEX				
SHORT ACTING BRONCHODILATORS - INHALERS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Minimum day supply of at 16 days is required	PROAIR RESPICLICK XOPENEX HFA	
PROAIR HFA PROVENTIL HFA VENTOLIN HFA				
SHORT ACTING BRONCHODILATORS - NEBULIZERS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	levalbuterol (BRAND IS PREFERRED)	
albuterol neb XOPENEX neb*				
STEROID INHALANTS		Trial and failure of three (3) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Alvesco will be approved for a history of oral thrush with steroid inhalants.	AEROBID/AEROBID-M ALVESCO ASMANEX PULMICORT SUSPENSION 1mg/2ml QVAR	
AEROSPAN budesonide FLOVENT HFA/DISK PULMICORT FLEXHALER				
EPINEPHRINE			ADRENACLICK (use preferred) AUVI-Q (use preferred) epinephrine (use preferred)	
EPI-PEN				

WYOMING MEDICAID
Preferred Drug List (PDL) - April 20, 2015

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>BASED ON LAST FULL INVENTORY PLEASE CONTACT US FOR QUESTIONS</small>
ALZHEIMERS	ALZHEIMER AGENTS donepezil EXELON PATCH/SOLUTION galantamine/ER NAMENDA/XR rivastigmine capsules		Client must have a diagnosis of dementia.	donepezil 23mg (use preferred) donepezil ODT (use preferred)
ANALGESICS	LONG-ACTING C-11s morphine sulfate ER tablets fentanyl patch 12.5, 25, 50, 75, and 100mg		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. C-11s and C-1Vs that are not included on the PDL and are available without prior authorization with the exception of Butrans (generic substitution is mandatory). Fentanyl patches will require a prior authorization unless a client has a cancer diagnosis or previous treatment of at least a 10 day supply within the last 45 days **Butrans requires a trial of morphine sulfate or low dose trial of fentanyl patch. ***Nucynta ER will be allowed for diabetic peripheral neuropathy or clients with significant gastrointestinal concerns with other CII narcotics. Fentanyl patches are limited to one patch every 72 hours.	AVINZA BUTRANS** fentanyl patch 37.5, 62.5, and 87.5mg hydromorphone ER HYSINGLA ER (additional criteria applies) KADIAN (10mg, 200mg) morphine sulfate ER capsules NUCYNTA ER*** OPANA ER (5mg, 10mg, 20mg, 30mg, 40mg) oxymorphone ER (7.5mg, 15mg) OXYCONTIN/CR XARTEMIS XR ZOHYDRO ER (additional criteria applies)
	SHORT-ACTING C-11s codeine sulfate hydrocodone/APAP hydrocodone/IBU hydromorphone LORTAB ELIXIR 10-300MG morphine sulfate oxycodone oxycodone/APAP oxycodone/ASA		Trial and failure of three (3) preferred agents greater than or equal to a 6 day supply in the last 90 days will be required before approval can be given for a non-preferred agent. **In addition to above criteria, Embeda and Oxecta require a diagnosis of drug/substance abuse. ***Nucynta will be allowed for diabetic peripheral neuropathy or clients with significant gastrointestinal concerns with other CII narcotics.	EMBEDA** levorphanol NUCYNTA*** OXECTA** oxymorphone oxycodone/IBU PRIMLEV ZOLVIT SOLUTION
	C-III/C-V AGENTS tramadol		Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Quantity and dosage limits apply (max 8 tabs/day). **Butrans will require a 14 day trial and failure of tramadol IR and a 14 day trial and failure of tramadol ER prior to approval	BUTRANS** CONZIP RYBIX ODT tramadol/apap tramadol ER
	ANDROGENS		TESTOSTERONE TOPICAL GELS ANDROGEL*	Testosterone agents are only allowed for diagnosis of hypogonadism or insufficient testosterone production. Other testosterone dosage form products will require a diagnosis of hypogonadism or insufficient testosterone production (not outlined on PDL).
ANTIBIOTICS	QUINOLONES ciprofloxacin/ER levofloxacin ofloxacin			FACTIVE moxifloxacin NOROXIN PROQUIN
	DOXYCYCLINE doxycycline			ADOKA (use preferred) DORYX (use preferred) ORACEA (use preferred)
	MINOCYCLINE minocycline/ER			SOLODYN (use preferred)
	INHALED TOBRAMYCIN BETHKIS TOBI*		Minimum day supply of at 56 days is required	inhaled tobramycin (BRAND IS PREFERRED) TOBI PODHALER (use preferred)
	ANTICOAGULANTS		LOW MOLECULAR WEIGHT HEPARIN (LMWH) enoxaparin	Prior authorization will be required for the 300mg/3ml strength
		DIRECT THROMBIN INHIBITOR PRADAXA	Client must have diagnosis of non-valvular atrial fibrillation and relative contraindication to warfarin for approval, treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE), or for the reduction in the risk of recurrence of DVT and PE after initial therapy.	
		SELECTIVE FACTOR XA INHIBITOR ELIQUIS XARELTO	Client must have diagnosis of non-valvular atrial fibrillation, treatment for deep vein thrombosis (DVT) prophylaxis in knee or hip replacement, treatment of DVT and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE after initial therapy.	
ANTICONSULSANTS	DIAZEPAM RECTAL GEL DIASTAT*			diazepam gel (BRAND IS PREFERRED)
	LACOSAMIDE VIMPAT		Client must have a diagnosis of partial onset seizures.	

WYOMING MEDICAID
Preferred Drug List (PDL) - April 20, 2015

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.					
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>BASED ON 2013 PDL. PLEASE CONTACT US FOR QUESTIONS.</small>	
ANTIDEPRESSANTS	ANTIDEPRESSANTS		<p>Trial and failure of two (2) preferred agents greater than or equal to six (6) weeks WITHIN THE LAST 2 YEARS will be required before approval can be given for a non-preferred agent. One of the trials of preferred agents must be in the same class (NaSS, NDRI, SSRI, or SNRI) as the requested non-preferred agent.</p> <p>Trazodone, bupropion, fluvoxamine, MAO inhibitors, TCA's, bupropion IR and venlafaxine IR do not require prior authorization but will not count towards meeting preferred therapy requirements.</p> <p>**Duloxetine will be approved for clients with a diagnosis of osteoarthritis of the knee or chronic low back pain.</p> <p>***Brintellix requires trial and failure of two preferred agents in any class</p> <p>Clients five (5) years of age and younger will require prior authorization before approval.</p> <p>Dosage limits apply: bupropion ER/SR/XL: 450mg/day citalopram ≤ 60 years of age: 60mg/day citalopram > 60 years of age: 30mg/day escitalopram: 30mg/day fluoxetine ≤ 18 years of age: 90mg/day fluoxetine > 18 years of age: 120mg/day mirtazapine: 67.5mg/day paroxetine IR/CR ≤ 18 years of age: 75mg/day paroxetine IR > 18 years of age: 90mg/day paroxetine CR > 18 years of age: 112.5mg/day sertraline: 300mg/day venlafaxine ER: 337.5mg/day</p>	<p>NaSS</p> <p>mirtazapine 7.5mg and rapid dissolve tablets (<i>use preferred</i>)</p>	
	NORADRENERGIC/SPECIFIC SEROTONERICS (NaSS)				
	mirtazapine 15, 30, and 45mg				
	NOREPINEPHRINE/DOPAMINE REUPTAKE INHIBITORS (NDRI)				
	bupropion ER/SR/XL				<p>NDRI</p> <p>ALENZIN FORFIVO XL</p>
	SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI)				
	citalopram escitalopram fluoxetine capsules paroxetine IR/CR sertraline				<p>SSRI</p> <p>fluoxetine tablets (<i>use preferred</i>) VIIBRYD</p>
SEROTONIN/NORPINEPHRINE REUPTAKE INHIBITORS (SNRI)					
venlafaxine ER capsules			<p>SNRI</p> <p>duloxetine** desvenlafaxine FETZIMA PRISTIQ venlafaxine ER tablets (<i>use preferred</i>)</p> <p>OTHER</p> <p>BRINTELLIX***</p>		
ANTHYPERTENSIVES	ACE INHIBITORS		<p>Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.</p>		
	benazepril captopril enalapril fosinopril lisinopril moexipril perindopril quinapril ramipril trandolapril				
	ACE INHIBITORS AND DIURETICS				
	benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ moexipril/HCTZ quinapril/HCTZ				
	ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)				
		DIOVAN* irbesartan losartan		<p>Trial and failure of an ACE Inhibitor greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for preferred ARB. Non-preferred ARBs and ARB/diuretic combinations also require a history of ALL preferred ARBs before approval can be given.</p>	<p>BENICAR candesartan EDARBI eprosartan 600mg telmisartan TEVETEN 400mg valsartan (BRAND IS PREFERRED)</p>
	ARBs AND DIURETICS				
	irbesartan HCTZ losartan HCT	<p>Trial and failure of an ACE Inhibitor greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for preferred ARB. Non-preferred ARBs and ARB/diuretic combinations also require a history of ALL preferred ARBs before approval can be given.</p>	<p>BENICAR HCT candesartan HCTZ EDARBYCLOR telmisartan HCTZ TEVETEN HCTZ valsartan HCTZ</p>		
ALPHA-BLOCKERS					
CATAPRES PATCHES* clonidine			<p>clonidine patch (BRAND IS PREFERRED) NEXICLON XR (<i>use preferred</i>)</p>		
ANTIVIRALS	PROTEASE INHIBITORS			<p>NORVIR solution (<i>use preferred</i>)</p>	
	APTIVUS CRIXIVAN INVIRASE LEXIVA NORVIR CAPSULES NORVIR TABLETS PREZISTA REYATAZ VIRACEPT				

WYOMING MEDICAID
Preferred Drug List (PDL) - April 20, 2015

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT US FOR QUESTIONS</small>
ANTIPSYCHOTICS	ATYPICAL ANTIPSYCHOTICS		<p>**Quetiapine doses less than 100mg will require prior authorization without a diagnosis of mood disorder or major depressive disorder. For titration doses, contact the GHS Pharmacy Help Desk for an override.</p> <p>Clients five (5) years of age and younger will require prior authorization before approval.</p> <p>Dosage limits apply: ABILIFY <13 years of age: 23mg/day ABILIFY ≥13 years of age: 45mg/day FANAPT: 36mg/day INVEGA: 18mg/day LATUDA: 240mg/day Risperidone ≤ 17 years of age: 5mg/day Risperidone > 17 years of age: 24mg/day SAPHRIS: 30mg/day Olanzapine < 13 years of age: 15mg/day Olanzapine ≥ 13 years of age: 30mg/day Quetiapine <13 years of age: 600mg/day Quetiapine 13-17 years of age: 900mg/day Quetiapine > 17 years of age: 1200mg/day ziprasidone ≤ 17 years of age: 180mg/day ziprasidone > 17 years of age: 300mg/day</p>	SEROQUEL XR (use preferred)
	SPECIAL ATYPICAL ANTIPSYCHOTICS		Dosage limits apply: 1350mg/day	VERSACLOZ Suspension (use preferred)
	clozapine			
CHOLESTEROL	BILE ACID SEQUESTERANT		Trial and failure of ALL preferred agents greater than or equal to six (6) months in the last 12 months will be required before approval can be given for a non-preferred agent.	WELCHOL
	cholestyramine/light colestipol			
	NIACIN			niacin ER (BRAND IS PREFERRED)
	NIASPAN*			
	STATINS, LOW POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	fluvastatin/ER
	lovastatin pravastatin		If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization.	
	STATINS, HIGH POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	CRESTOR LIVALO
atorvastatin simvastatin		If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization.		
STATIN COMBINATIONS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ADVICOR (use separate agents) amiodopine/atorvastatin (BRAND IS PREFERRED) CHOLESTIN LIPTRUZET PRAVIGARD SIMCOR ZETIA** (use preferred)	
CADUET* VYTORIN		**Zetia monotherapy will require PA.		
TRIGLYCERIDE LOWERING AGENTS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ANTARA fenoibrific fenoibrate 43, 50, 130, and 150mg FENOGLIDE LIPOFEN LOVAZA VASCEPA	
fenofibrate 54, 67, 134, 145, 160, and 200mg gemfibrozil				

WYOMING MEDICAID
Preferred Drug List (PDL) - April 20, 2015

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS CELL IS NOT FULL INCLUSIVE PLEASE CONTACT US FOR QUESTIONS</small>
CONTRACEPTIVES	ORAL CONTRACEPTIVES			amethia/LO (BRAND IS PREFERRED) alyacen (BRAND IS PREFERRED) aranelle (BRAND IS PREFERRED) BEYAZ (PA required) camila (use preferred) camrese/LO (BRAND IS PREFERRED) cyclafem (BRAND IS PREFERRED) dasetta (BRAND IS PREFERRED) daysee (BRAND IS PREFERRED) deblitane (use preferred) drospir/ethi (use preferred) GENERESS FE CHW (PA required) heather (use preferred) introvale (use preferred) jencycla (use preferred) levonorgest/ethinyl estrad (91-Day) (use preferred) leena (BRAND IS PREFERRED) loestrin 21, FE 1/20, FE 1.5/30 (use preferred) LO LOESTRIN (PA required) LO MINASTRIN FE (PA required) loryna (use preferred) MINASTRIN 24 FE CHEWABLE (PA required) MODICON (use preferred) NATAZIA (PA required) necon 0.5/35, 1/35, 7/7/7 (BRAND IS PREFERRED) NECON 1/50 (use preferred) nikki (use preferred) norethindrone (use preferred) NORINYL 1/35 (use preferred) norlyroc (use preferred) nor-qd (use preferred) nortrel (BRAND IS PREFERRED) ortho micron (use preferred) pirmella (BRAND IS PREFERRED) quasense (use preferred) QUARTETTE (PA required) SAFYRAL (PA required) sharobel (use preferred) tilia FE (BRAND IS PREFERRED) tri-legest FE (BRAND IS PREFERRED) wera (BRAND IS PREFERRED) wymzya FE chewable (BRAND IS PREFERRED) zenchent FE chewable (PA required) zeosa chewable (BRAND IS PREFERRED)
	altavera AMETHYST azurette apri aubra aviane balzia BREVICON* briellyn caziant chateal cryselle delyla DESOGEN deso/ethinyl estradiol elinest emoquette enpresse enskyce errin estarylla ESTROSTEP FE* falmina Femcon FE Chewable gianvi gildagia gildess/FE jolessa jolviette junel/FE kariva kelnor kurvelo larin/FE lessina levonest levonor/ethi levora LOESTRIN 24 FE LOMEDIA 24 FE LOSEASONIQUE low-ogestrel lutura lyza marlissa microgestin/FE mono-linyah mononessa myzila NECON 10/11-28 nora-be norgest/ethinyl estradiol noreth/ethin FE 1/20 NORINYL 1/50-28 ocella OGESTREL orsythia ORTHO-CEPT ORTHO TRI-CYCLEN LO* ORTHO-NOVUM 1/35-28, 7/7/7-28* philith pimtrea portia previfem reclipsen SEASONIQUE* sprintec sronyx syeda tri-estaryl tri-linyah trinessa TRI-NORINYL* tri-previfem tri-sprintec trivora velivet vestura viorele vyfemla zarah zenchent ZOVIA			
CORTICOSTEROIDS	ORAL CORTICOSTEROIDS			CELESTONE (use preferred)
	budesonide cortisone acetate dexamethasone/intensol hydrocortisone methylprednisone prednisolone prednisone			

WYOMING MEDICAID
Preferred Drug List (PDL) - April 20, 2015

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS CELL IS NOT FULLY INCLUSIVE PLEASE CONTACT US FOR QUESTIONS</small>
DIABETES	DIABETES AGENTS			FORTAMET (<i>use preferred</i>) GLUMETZA (<i>use preferred</i>) RIOMET (<i>use preferred</i>)
	BIGUANIDES			
	metformin/ER			
	α-GLUCOSIDASE INHIBITORS			GLYSET
	acarbose		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	MEGLITINIDES			nateglinide (BRAND IS PREFERRED) repaglinide
	STARLIX*		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	THIAZOLIDINEDIONES			ACTOSPLUS MET (<i>use separate agents</i>) AVANDIA AVANDAMET (<i>use separate agents</i>)
	pioglitazone		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	SULFONYLUREAS			
	glimepiride/ER glipizide/ER glyburide/ER		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS			GLYXAMBI (<i>use separate preferred agents</i>)
		JANUVIA ONGLYZA	Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	NESINA TRADJENTA
	DPP-4 INHIBITOR COMBO AGENTS			JENTADUETO JUVISYNC KAZANO OSENI
		JANUMET/XR KOMBIGLYZE	Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	
	INCRETIN MIMETICS (GLP-1 RECEPTOR AGONISTS)			BYDUREON BYETTA TANZEUM TRULICITY
		VICTOZA	Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	
	SGLT2 INHIBITORS			GLYXAMBI (<i>use separate preferred agents</i>)
	FARXIGA INVOKANA	Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	JARDIANCE	
SGLT2 INHIBITOR COMBO AGENTS				
	INVOKAMET XIGDUO XR	Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.		
LONG-ACTING INSULIN			LANTUS OPTICLIK (<i>use preferred</i>) TOUJEO (<i>use preferred</i>)	
LANTUS SOLOSTAR LANTUS vial LEVEMIR		Prior authorization will be required when using two different delivery forms of the same type of insulin concurrently		
DIABETIC METERS/TEST STRIPS			ALL OTHER METERS AND TEST STRIPS	
	FREESTYLE INSULINX FREESTYLE LITE FREESTYLE FREEDOM LITE ONE TOUCH ULTRA ONE TOUCH ULTRA 2 ONE TOUCH ULTRA MINI ONE TOUCH ULTRASMART ONE TOUCH VERIO PRECISION XTRA	Quantity limits apply: Insulin Dependent Clients: 10 strips/day Non-Insulin Dependent Clients: 4 strips/day Clients are limited to 1 meter/365 days		
EAR	ANTIBIOTIC/STEROID COMBINATION			ciprofloxacin 0.2% (<i>use preferred</i>) CIPRO HC (<i>use preferred</i>) COLY-MYCIN S (<i>use preferred</i>) CORTISPORIN-TC (<i>use preferred</i>) FLUOCINOLONE ACET OIL 0.01% (<i>use preferred</i>)
	CIPRODEX Neo/Poly/HC Suspension and Solution Ofloxacin			
FIBROMYALGIA	FIBROMYALGIA STEP 1			
	amitriptyline cyclobenzaprine			
	FIBROMYALGIA STEP 2			
	SAVELLA	Trial and failure of a Step 1 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 2 agent.		
FIBROMYALGIA STEP 3				
	duloxetine LYRICA	Trial and failure of a Step 1 agent and a Step 2 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 3 agent.		
GASTROINTESTINAL	DIGESTIVE ENZYMES			PANCREAZE pancreliopase (BRAND IS PREFERRED) PERTZYE TRI-PASE ULTRESA VIOKASE
	CREON 3000, 6000, 12000, 24000, and 36000 units ZENPEP*		Prior authorization required.	
	IRRITABLE BOWEL SYNDROME AGENTS			
	CHLORIDE CHANNEL ACTIVATOR			
		AMITIZA	Client must have a diagnosis of opioid-induced constipation and a three (3) month trial and failure of a secretory agent, or a diagnosis of chronic idiopathic constipation or Irritable Bowel Syndrome (IBS) with constipation.	
	GUANYLATE CYCLASE-C AGONIST			
	LINZESS	Client must have a diagnosis of chronic idiopathic constipation or Irritable Bowel Syndrome (IBS) with constipation.		
PROTON PUMP INHIBITORS			ACIPHEX SPRINKLES amox/clarith/lanso pack (<i>use separate agents</i>) DEXILANT esomeprazole 24.65mg and 49.3mg lansoprazole solutabs NEXIUM* omeprazole 20.6mg capsules (<i>use preferred</i>) omeprazole tablets (<i>use preferred</i>) omeprazole/sodium bicarbonate OMECLAMOX (<i>use separate agents</i>) rabeprazole VIMOVO (<i>use separate agents</i>)	
	lansoprazole capsules omeprazole capsules pantoprazole	Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Lansoprazole solutabs will be approved for children less than or equal to 8 years of age.		

WYOMING MEDICAID
Preferred Drug List (PDL) - April 20, 2015

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.					
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT US FOR QUESTIONS</small>	
GASTROINTESTINAL continued	MESALAMINE		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ASACOL/HD CANASA LIALDA PENTASA 500MG (<i>use preferred</i>) ROWASA	
	APRISO mesalamine enema PENTASA 250MG ONLY				
GROWTH HORMONE	GROWTH HORMONE		PA is required for use outside of FDA-approved indications. Evaluation by an endocrinologist is preferred. Clinical evidence of improved growth will be required on a yearly basis to support ongoing utilization. Clinical evidence of need for growth hormone will be required for adult growth hormone deficiency and pediatric growth failure due to inadequate endogenous growth hormone. Trial and failure of two (2) preferred agents within the last 12 months will be required for the following indications: Pediatric: Growth failure due to inadequate endogenous growth hormone, Prader-Willi syndrome, children born small for gestation. Turner syndrome. Adult: Replacement for those with growth hormone deficiency.	NUTROPIN AQ OMNITROPE SAIZEN SEROSTIM TEV-TROPIN ZORBITIVE	
		GENOTROPIN NORDITROPIN HUMATROPE			
HEPATITIS C	INTERFERON		Trial and failure of preferred agent greater than or equal to 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Peg-Intron will be approved for pediatric patients (aged 18 and under), for retreatment, and for dosage adjustments that cannot be achieved with Pegasys.	PEG-INTRON	
	PEGASYS				
	NUCLEOTIDE ANALOG POLYMERASE INHIBITOR				Prior authorization is required prior to use of Sovaldi. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org .
		SOVALDI			
	PROTEASE INHIBITOR				Prior authorization is required prior to use of Olysio. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org .
	OLYSIO				
HEP C COMBO AGENTS		Prior authorization is required prior to use of Harvoni or Viekira Pak. Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org .			
	HARVONI VIEKIRA PAK				
IMMUNOMODULATORS	IMMUNOMODULATORS		Client must have one of the diagnoses prior to approval for preferred agents (outlined below): Enbrel: Ankylosing Spondylitis (AS), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PA), Plaque Psoriasis (PP), and Rheumatoid Arthritis (RA)** Humira: AS, Crohn's, JIA, PA, PP, Ulcerative Colitis (UC), RA** **56-day trial and failure of methotrexate required prior to approval of a preferred agent (Enbrel or Humira) for diagnosis of Rheumatoid Arthritis (RA). For non-preferred agents with a diagnosis of AS, JIA, PP, PA, and RA, a 56-day trial and failure of both preferred agents is required. For non-preferred agents with a diagnosis of Crohn's or UC, a 56-day trial and failure of Humira is required. The approved diagnoses for the non-preferred agents are outlined below: Actemra: RA** Amevive: PP Cimzia: AS, Crohn's, PA, RA** Kineret: RA Orencia: JIA, RA** Otezla: PA, PP Remicade: AS, Crohn's, PA, PP, RA**, UC Rituxan: RA** Simponi: AS, PA, RA** Stelara: PP Tysabri: Crohn's (additional PA criteria applies) Xelanz: RA**	ACTEMRA AMEVIVE CIMZIA KINERET ORENCIA OTEZLA RAPTIVA REMICADE RITUXAN SIMPONI STELARA TYSABRI (<i>additional criteria applies</i>) XELIANZ	
		ENBREL HUMIRA			
INSOMNIA	NON-BENZODIAZEPINES		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Prior authorization will be required for clients under the age of 18. Rozerem is non-preferred without a history of substance abuse Prior authorization will be required when a client is taking more than one insomnia agent concurrently. Dosage limits apply: zaleplon: 30mg/day zolpidem: 15mg/day	BELSOMRA EDLUAR (<i>additional criteria applies</i>) eszopiclone INTERMEZZO (<i>additional criteria applies</i>) ROZEREM zolpidem ER ZOLPIMIST (<i>additional criteria applies</i>)	
	zaleplon zolpidem				

WYOMING MEDICAID
Preferred Drug List (PDL) - April 20, 2015

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>BASED ON WHAT HAS BEEN INCLUDED IN THE CONTRACTS SET FOR NEGOTIATION</small>
MIGRAINE	naratriptan sumatriptan	TRIPHTANS	Trial and failure of all preferred agents will be required for approval of a non-preferred agent. Rizatriptan will be approved for clients between 6 and 17 years of age Quantity limits apply: naratriptan 1mg: 25 tabs/34 days naratriptan 2.5mg: 10 tabs/34 days sumatriptan vials: 2 vials/34 days sumatriptan nasal: 6 bottles/34 days sumatriptan 25mg: 41 tabs/34 days sumatriptan 50mg: 20 tabs/34 days sumatriptan 100mg: 10 tabs/34 days	AXERT FROVA RELPAX rizatriptan TREXIMET zolmitriptan
MULTIPLE SCLEROSIS	STEP 1 MS AGENTS IMMUNOMODULATOR (GLATIRAMER INJECTION)		Trial and failure of one preferred agent will be required before approval can be given for the step 2 MS agent (Gilenya).	AUBAGIO COPAXONE 40MG/ML (use preferred) EXTAVIA LEMTRADA
	COPAXONE 20MG/ML			PLEGRIDY
	INTERFERON		Trial and failure of a preferred step 1 interferon agent AND trial and failure of Copaxone 20mg/ml will be required before approval can be given for a non-preferred agent.	REBIF TECFIDERA
	AVONEX BETASERON			TYSABRI (additional criteria applies)
NEUROPATHIC PAIN	STEP 2 MS AGENTS		For Tysabri, in addition to the above criteria, additional prior authorization criteria applies.	
		GILENYA		
NEUROPATHIC PAIN	TRICYCLIC ANTIDEPRESSANTS		For the diagnosis of neuropathic pain, trial and failure of a tricyclic antidepressant greater than or equal to a 12 week supply AND trial and failure of gabapentin at a dose of 3600mg per day for greater than or equal to a 12 week supply in the last 12 months will be required before approval can be given for a non-preferred agent.	duloxetine LYRICA
		amitriptyline desipramine imipramine nortriptyline		
NSAIDS	GABAPENTIN			
		gabapentin		
NSAIDS	NSAIDs		Trial and failure of two (2) preferred agents each greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Dosing and quantity limits apply for ketorolac (limit 5days/34 days; max dose 40mg/day for oral tablets).	CALDOLOR (use preferred) CAMBIA POWDER (use preferred) celecoxib diclofenac 1.5% solution (additional criteria applies) diclofenac 3% gel (additional criteria applies) fenoprofen FLECTOR (additional criteria applies) mefenamic acid NEOPROFEN (use preferred) SPRIX (additional criteria applies) VOLTAREN (additional criteria applies) ZIPSOR (use preferred) ZORVOLEX (use preferred)
	diclofenac tablets etodolac flurbiprofen ibuprofen indomethacin ketoprofen ketorolac meclizolam meloxicam nabumetone naproxen oxaprozin piroxicam sulindac tolmetin			
OPHTHALMICS	OP. -ANTI-ALLERGICS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Emadine, Alomide, and Alocril will be approved for pregnancy. Alomide will be approved for children under the age of 3.	ALAMAST ALOCRIL ALOMIDE ALREX azelastine (BRAND IS PREFERRED) BEPREVE ELESTAT EMADINE ketotifen LASTACAFT PAZEO
	OP. -ANTIBIOTICS- QUINOLONES		Trial and failure of a preferred agent greater than or equal to 5 days in the last 12 months will be required before approval can be given for a non-preferred agent. Azasite will be approved for pregnancy.	AZASITE BESIVANCE gatifloxacin IQIUX levofloxacin ZYMAR
	OP. -ANTI-INFLAMMATORY- NSAIDS		Trial and failure of ALL preferred agents each greater than or equal to 5 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ACULAR/LS/PF (use preferred) ACUVAIL BROMDAY bromfenac ILEVRO NEVANAC
	OP. -BETA-BLOCKERS		Trial and failure of three (3) preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Betoptic S will be approved for those with heart and lung conditions.	BETIMOL BETOPTIC S ISTALOL
	OP. -CARBONIC ANHYDRASE INHIBITOR		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	AZOPT
	OP. -COMBO PRODUCTS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	
	COMBIGAN dorzolamide/timolol SIMBRINZA			
	OP. -PROSTAGLANDINS		Trial and failure of ALL preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	LUMIGAN ZIOPTAN
	latanoprost TRAVATAN Z			
	OP. -SYMPATHOMIMETICS		Trial of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	ALPHAGAN P 0.1% brimonidine 0.15% (BRAND IS PREFERRED) COMBIGAN (use separate agents)
		ALPHAGAN P 0.15%* brimonidine 0.2%		

WYOMING MEDICAID
Preferred Drug List (PDL) - April 20, 2015

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates , and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES
OSTEOPOROSIS	BISPHOSPHONATES		Trial and failure of a preferred agent greater than or equal to 12 months will be required before approval can be given for a non-preferred agent. Fosamax liquid will be approved for clients that have difficulty swallowing.	risedronate ATELVIA FOSAMAX-D ibandronate
	alendronate			
	NASAL CALCITONIN			
	calcitonin-salmon fortical			
OVERACTIVE BLADDER	OVERACTIVE BLADDER AGENTS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Oxytrol will be approved for clients that have an inability to swallow.	ENABLEX GELNIQUE GEL 10% MYRBETRIQ OXYTROL DIS SANCTURA XR tolterodine/ER trospium
PHOSPHATE BINDERS	PHOSPHATE BINDERS		Prior authorization required for non-preferred agents.	AURYXIA FOSRENOL sevelamer VELPHORO
PLATELET AGGREGATE INHIBITORS	THIENOPYRIDINE DERIVATIVES		Prior authorization required for clients on antiplatelet therapy greater than one (1) year.	
	clopidogrel EFFIENT ticlopidine			
	CPTP DERIVATIVES		Prior authorization is required.	BRILINTA
	PAR-1 ANTAGONIST		Client must have diagnosis reduction of thrombotic cardiovascular events with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). Must be used in conjunction with aspirin or clopidogrel.	
		ZONTIVITY		
PROGESTIN	PROGESTIN		Prior authorization is required.	
		MAKENA		
PROSTATE	5-ALPHA-REDUCTASE INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	AVODART JALYN (use separate agents)
	finasteride			
	ALPHA BLOCKERS		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	alfuzosin JALYN (use separate agents) RAPAFLO
	doxazosin tamsulosin terazosin			
PULMONARY ANTIHYPERTENSIVES	5-ALPHA-REDUCTASE INHIBITORS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	
		ADICRA REVATIO SUSPENSION sildenafil (Revatio A/B rated generic)		
	ENDOTHELIN RECEPTOR ANTAGONISTS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	OPSUMIT
		LETAIRIS TRACLEER		
	SOLUBLE GUANYLATE CYCLASE STIMULATORS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	
		ADEMPAS		
	PROSTACYCLINE VASODILATOR		Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	
		ORENITRAM		
RESTLESS LEG SYNDROME	RESTLESS LEG SYNDROME		Client must have a diagnosis of Restless Leg Syndrome (RLS). Trial and failure of gabapentin greater than or equal to 60 days and a trial and failure of a dopamine agonist greater than or equal to 60 days in the last 12 months will be required before approval can be given for a non-preferred agent. *Neupro will be approved for clients with difficulty swallowing or for clients with a diagnosis of Parkinson's Disease.	HORIZANT NEUPRO*
		eabaoentin pramipexole ropinirole		
SKELETAL MUSCLE RELAXANTS	MUSCLE RELAXANTS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months, along with a medical diagnosis of muscle spasticity will be required before approval can be given for a non-preferred agent. Cyclobenzaprine will require a prior authorization for clients concurrently taking a tricyclic antidepressant.	carisoprodol chlorzoxazone cyclobenzaprine ER metaxalone methocarbamol orphenadrine tizanidine capsules (use preferred) Carisoprodol is limited to 84 tabs/365 days
	baclofen cyclobenzaprine tizanidine tablets			

WYOMING MEDICAID
Preferred Drug List (PDL) - April 20, 2015

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT US FOR QUESTIONS</small>
STIMULANT	AMPHETAMINES		Clients must have a diagnosis for ADD, ADHD, narcolepsy, obstructive sleep apnea, shift work sleep disturbance, MS fatigue (see MS Fatigue criteria below), or refractory depression (see refractory depression criteria below).	AMPHETAMINES: dextroamphetamine CR capsules (BRAND IS PREFERRED) ZENZEDI 2.5 AND 7.5MG TABLETS
	LONG ACTING AMPHETAMINES			
	amphetamine salts combo XR DEXEDRINE CAPSULES* VYVANSE		Diagnosis of MS fatigue will require a fatigue severity scale score of 5.0, a 60-day trial of amantadine and discontinuation of medications that may contribute to drowsiness and fatigue.	
	IMMEDIATE RELEASE AMPHETAMINES			
	amphetamine salts combo* dextroamphetamine tablets		Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant.	METHYLPHENIDATES: dexmethylphenidate ER (BRAND IS PREFERRED) methylphenidate ER/CR/SR capsules (METADATE CD/RITALIN LA) QUILLIVANT XR SUSPENSION
	METHYLPHENIDATES			
	LONG ACTING METHYLPHENIDATES		Prior Authorization will be required for clients under the age of 4.	
DAYTRANA FOCALIN XR methylphenidate ER/CR/SA/SR tablets				
IMMEDIATE RELEASE METHYLPHENIDATES		Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use.		
dexmethylphenidate methylphenidate tablets methylphenidate				
STIMULANT-LIKE AGENTS	SELECTIVE ALPHA-ADRENERGIC AGONIST		To obtain the non-preferred agent , client must meet the following criteria: Client must have a diagnosis of ADD or ADHD Prior authorization will be required for clients under the age of 4. Clients must have completed a 14 day trial of clonidine IR with <u>benefit</u> in the previous 12 months.	KAPVAY*
	clonidine			
	GUANFACINE AGENTS		To obtain the non-preferred agent , client must meet the following criteria: Client must have a diagnosis of ADD or ADHD Prior authorization will be required for clients under the age of 4. Clients must have a trial and failure of a stimulant greater than or equal to a 14 day supply OR a trial and failure of Strattera greater than or equal to a 30 day supply AND a 14 day trial of guanfacine with <u>benefit</u> in the previous 12 months, OR a contraindication to ADHD medications (including stimulant and non-stimulant), OR a TIC disorder associated with stimulants (trial of stimulant required).	guanfacine ER
guanfacine				
SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR		Clients must have a diagnosis for ADD, ADHD, narcolepsy, obstructive sleep apnea, shift work sleep disturbance, or refractory depression (see refractory depression criteria below). Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant. Prior Authorization will be required for clients under the age of 4. Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use. Dosage limits apply: STRATTERA: 150mg/day		
STRATTERA				

WYOMING MEDICAID
Preferred Drug List (PDL) - April 20, 2015

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), Epocrates, and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT US FOR QUESTIONS</small>
TOPICAL AGENTS	IMPETIGO ANTIBIOTICS		Trial and failure of ALL preferred agents greater than or equal to 7 days in the past 90 days. Use smallest size appropriate for 7 day trial.	ALTABAX
	gentamicin mupirocin			
	BENZOYL PEROXIDE/CLINDAMYCIN COMBOS		Clients must be 12 to 20 years of age and have a diagnosis of acne vulgaris. Requires prior authorization for clients less than 12 years of age. Acne combinations are limited to clients under the age of 21.	ACANYA benzoyl peroxide/clindamycin (BRAND IS PREFERRED)
		BENZAFLIN* clindamycin/benzoyl peroxide 1.2 (1)-5% (Refrig)		
	CORTICOSTEROIS		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	PANDEL prednicarbate 0.1% (C,O) TEXACORT 2.5% (S)
	LOW POTENCY			
	alclometasone desonide DESOWEN 0.05% (L) fluocinolone 0.01% hydrocortisone butyrate 0.1% (C) hydrocortisone 1%, 2.5% (C,L,O) SYNALAR 0.01%			
	MEDIUM POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	Clocortolone Pivalate CORDRAN/SP fluticasone 0.05% (L) hydrocortisone butyrate 0.1% (O) TOPICORT LP TRIANEX
	betamethasone valerate CUTIVATE 0.05% (C) DERMATOP 0.1% (C) desoximetasone 0.05% (C) ELOCON 0.1% fluocinolone 0.025% fluticasone 0.05% (C) hydrocortisone probutate 0.1% (C) mometasone SYNALAR 0.025% TOPICORT 0.05% (C) triamcinolone 0.025%, 0.1%			
	HIGH POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	APEXICON amcinonide 0.1% (C,L,O) augmented betamethasone 0.05% (G,L,O) clobetasol 0.05% (L) desoximetasone 0.05%, 0.25% (C,G,O) fluocinonide 0.1% (C) HALOG
	betamethasone dipropionate clobetasol/E 0.05% (C,G,O,S) diflorasone DIPROLENE 0.05% (L) fluocinonide flurandrenolide fluticasone 0.005% (O) halobetasol TEMOVATE/E TOPICORT 0.25% (C) triamcinolone 0.5% ULTRAVATE 0.05%			
	IMMUNOMODULATORS		Trial and failure of a preferred medium potency topical corticosteroid greater than or equal to a 21 day trial <u>and</u> a trial and failure of a preferred high potency topical corticosteroid greater than or equal to a 21 day trial in the last 90 days. For clients less than two (2) years of age, a trial and failure of a preferred low potency corticosteroid greater than or equal to a 21 day trial <u>and</u> a trial and failure of a preferred medium potency topical corticosteroid greater than or equal to a 21 day trial in the last 90 days.	
	ELIDEL PROTOPIC			
SALICYLIC ACID			All other topical salicylic acid formulations.	
aliclen shampoo 6% salacyn cream/lotion 6% Salicylic Acid Shampoo 6%				
SCABICIDES/PEDICULICIDES		Trial and failure of a preferred agent in the last 12 months.	OVIDE permethrin cream SKLICE ULESFIA	
LINDANE NATROBA permethrin solution				
UREA			All other topical urea formulations.	
Kerafoam Aerosol 30% Remeven Cream 50% urea hydration aerosol 35% urea emulsion 50% urea nail suspension 40% urea suspension 50% X-Viate Cream 40%				